<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0001631'>atrial septal defect</z:hpo> occluder system (ASDOS) (Osypka Corp., Grenzach-Wyhlen, Germany) has been used clinically for transcatheter closure of <z:hpo ids='HP_0001684'>secundum atrial septal defect</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>) and <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) after episodes of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> over the last 10 years </plain></SENT>
<SENT sid="1" pm="."><plain>In this article, the up-to-date experience with this system is reviewed </plain></SENT>
</text></document>